Cargando…

Relapse in stage I(E) diffuse large B‐cell lymphoma

Despite a general favourable outcome in limited stage diffuse large B‐cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nijland, Marcel, Boslooper, Karin, van Imhoff, Gustaaf, Kibbelaar, Robbie, Joosten, Peter, Storm, Huib, van Roon, Eric N., Diepstra, Arjan, Kluin‐Nelemans, Hanneke C., Hoogendoorn, Mels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947732/ https://www.ncbi.nlm.nih.gov/pubmed/29083044 http://dx.doi.org/10.1002/hon.2487

Ejemplares similares

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
por: Nijland, Marcel, et al.
Publicado: (2017)

Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
por: Rozema, Johanne, et al.
Publicado: (2022)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population‐based study
por: Rozema, Johanne, et al.
Publicado: (2021)

Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma
por: Liang, Zheng, et al.
Publicado: (2014)

PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma
por: Liu, Yuxuan, et al.
Publicado: (2013)

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas
por: Wu, Rui, et al.
Publicado: (2016)

Primary Epstein–Barr virus infection diffusing F(18)-fluorodeoxyglucose-positron emission tomography/computed tomography response monitoring of Hodgkin’s disease: a case report
por: Balink, Hans, et al.
Publicado: (2014)

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
por: Doorduijn, Jeanette K., et al.
Publicado: (2020)

Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
por: Plaça, Jessica Rodrigues, et al.
Publicado: (2022)

Tumour necrosis as assessed with (18)F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
por: Kahle, Xaver U., et al.
Publicado: (2019)

Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy
por: Oortgiesen, Berdien E., et al.
Publicado: (2023)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes
por: Weston-Bell, Nicola J., et al.
Publicado: (2014)

HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
por: Huang, Xin, et al.
Publicado: (2012)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report
por: van Bentum, Renée, et al.
Publicado: (2019)

Case report of a clinically indolent but morphologically high‐grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?
por: Wardle, Claire L. W., et al.
Publicado: (2021)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
por: de Jong, Mathilde R. W., et al.
Publicado: (2018)

Somatic changes in B-lymphoproliferative disorders (B-LPD) detected by DNA-fingerprinting.
por: de Jong, D., et al.
Publicado: (1988)

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
por: Kersten, Marie José, et al.
Publicado: (2020)

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
por: Bult, Johanna A. A., et al.
Publicado: (2023)

Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Visser, Lydia, et al.
Publicado: (2016)

CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma
por: Sattarzadeh, Ahmad, et al.
Publicado: (2015)

High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study
por: Oortgiesen, B. E., et al.
Publicado: (2021)

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127
por: Sattarzadeh, Ahmad, et al.
Publicado: (2018)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
por: Brink, Mirian, et al.
Publicado: (2023)

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach
por: de Groot, Fleur A., et al.
Publicado: (2022)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

How I manage patients with relapsed/refractory diffuse large B cell lymphoma
por: Gisselbrecht, Christian, et al.
Publicado: (2018)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
por: van Doesum, Jaap A., et al.
Publicado: (2021)

CD27(+)CD38(hi) B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients
por: von Borstel, Anouk, et al.
Publicado: (2019)

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
por: Scheubeck, Gabriel, et al.
Publicado: (2023)

The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics
por: Kilsdonk, Melvin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_btr225c6c4393bb0083vj4ogn8